Applies AJCC 8th edition TNM staging with pathologic and clinical stage documentation. Use when staging cancers, applying TNM classifications, or documenting cancer stage.
Applies AJCC 8th edition TNM staging with pathologic and clinical stage documentation.
Why This Skill Exists
Accurate cancer staging is the single most consequential classification in oncology — it determines treatment eligibility, prognosis, clinical trial candidacy, and insurance authorization. The AJCC 8th edition (effective January 2018) introduced site-specific prognostic stage groups for breast, prostate, and other cancers that incorporate biomarkers beyond anatomy alone. Incorrect staging leads to inappropriate treatment, denied claims, and flawed tumor registry data.
Commission on Cancer (CoC) accreditation requires documented staging per AJCC guidelines within established timeframes. State cancer registries mandated by the National Program of Cancer Registries (NPCR) and SEER depend on correct stage assignment. Errors discovered post-treatment can trigger CoC compliance reviews and affect facility quality metrics.
Checkpoint A: Pre-Draft Intake (Mandatory)
What is the primary cancer site and histologic type? (Default: specify ICD-O-3 topography and morphology codes)
Is this a clinical stage (cTNM), pathologic stage (pTNM), or post-therapy stage (ypTNM)? (Default: clinical)
相关技能
Has definitive surgery been performed? If yes, provide surgical pathology report. (Default: pending)
What edition of AJCC staging is required? (Default: 8th edition)
Are biomarker results available (ER/PR/HER2 for breast, PSA/Gleason for prostate, etc.)? (Default: pending)
Is there evidence of distant metastasis on imaging? (Default: not assessed)
Has neoadjuvant therapy been administered prior to staging? (Default: no)
What is the laterality for paired organs? (Default: not applicable)
Documents to Request
Surgical pathology report with margin status and lymph node counts
Diagnostic imaging reports (CT, PET/CT, MRI, bone scan)
Biopsy/cytology reports with histologic grade
Biomarker and molecular testing results
Operative notes documenting extent of resection
Prior staging documentation if restaging after treatment
Endoscopy or bronchoscopy reports when applicable
Step 1: Identify Primary Site and Apply Site-Specific Staging Rules
Confirm the primary cancer site using ICD-O-3 topography codes. Each AJCC chapter has site-specific rules — do not apply generic TNM criteria across sites.
Key site-specific considerations in AJCC 8th edition:
Site
Major 8th Edition Change
Breast
Prognostic stage incorporates grade, ER, PR, HER2, Oncotype DX
Prostate
Prognostic stage uses PSA and Grade Group (replacing Gleason)
HPV+ Oropharynx
Separate staging system (p16 positive = different chapter)
Pancreas
T stage redefined by size (replacing vessel involvement)
Liver (HCC)
New staging chapter added
Cervix
Imaging and pathology now permitted for staging
For each primary site, confirm: (a) correct AJCC chapter, (b) required biomarkers for prognostic staging, (c) applicable staging classification type (clinical vs. pathologic).
Step 2: Assign T, N, and M Categories
T (Primary Tumor):
TX: primary tumor cannot be assessed
T0: no evidence of primary tumor
Tis: carcinoma in situ
T1–T4: increasing size and/or local extent (site-specific definitions)
N (Regional Lymph Nodes):
NX: regional nodes cannot be assessed
N0: no regional node metastasis
N1–N3: increasing number or extent of regional node involvement
M0: no distant metastasis (note: clinical M0 requires no confirmatory imaging — it is assigned when no evidence of metastasis exists)
M1: distant metastasis present — subcategorize by site when applicable (M1a, M1b, M1c per site-specific rules)
Record the prefix for each category: c (clinical), p (pathologic), yp (post-neoadjuvant pathologic), yc (post-neoadjuvant clinical), r (recurrence).
Step 3: Determine Anatomic and Prognostic Stage Groups
After assigning T, N, M categories, map to stage group:
Standard anatomic stage grouping:
Stage
General Criteria
Stage 0
Tis, N0, M0
Stage I
Small primary, node-negative
Stage II
Larger primary or limited node involvement
Stage III
Locally advanced or significant node involvement
Stage IV
Distant metastasis (any T, any N, M1)
For sites with prognostic staging (breast, prostate), apply biomarker modifiers. Example for breast: anatomic Stage IIA (T2N0M0) may become Prognostic Stage IA if ER+/PR+/HER2−, Grade 1, and favorable Oncotype DX score.
Always document both anatomic and prognostic stage groups when prognostic staging is defined for the site.
Step 4: Document Stage with Required Data Elements
Each stage assignment must include:
Staging basis — clinical, pathologic, or post-therapy
T category with size in centimeters and local extent descriptors
N category with number of nodes examined and number positive
M category with site of metastasis if M1
Overall stage group — both anatomic and prognostic when applicable
Biomarker values incorporated into prognostic staging
Grade per site-specific grading system (Nottingham for breast, Grade Group for prostate, differentiation for soft tissue sarcoma)
Date of diagnosis used as the staging reference date
If any component is unknown, record as X (e.g., NX) — never leave blank or assume normal.
Step 5: Handle Special Staging Scenarios
Multiple primaries: Apply AJCC multiple primary rules — stage each independently. Synchronous bilateral breast cancers are staged separately.
Unknown primary (CUP): Stage as TX. The N and M categories reflect the identified disease.
Restaging after recurrence: Use the "r" prefix (rTNM). Do not alter the original stage.
Post-neoadjuvant: Use "yp" prefix. Document pre-treatment clinical stage and post-treatment pathologic stage separately.
Lymphoma and leukemia: Use Ann Arbor (Lugano modification) or disease-specific staging — not TNM.
Pediatric tumors: Many use disease-specific systems (e.g., INSS for neuroblastoma, FIGO for pediatric germ cell tumors).
Checkpoint B: Post-Draft Alignment (Mandatory)
Does the assigned stage match the AJCC 8th edition chapter for this specific cancer site?
Are all TNM categories documented with the correct prefix (c, p, yp, r)?
For sites with prognostic staging, are required biomarkers included and the prognostic stage group assigned?
Is the number of lymph nodes examined and number positive recorded for pathologic staging?
Does the stage assignment align with the imaging and pathology findings provided?
Quality Audit
Correct AJCC edition and chapter applied for the primary site
T category matches tumor size and extent per site-specific rules
N category includes node count data for pathologic staging
M category supported by imaging documentation
Clinical vs. pathologic vs. post-therapy prefix correctly assigned
Stage group correctly derived from TNM combination
Prognostic stage group assigned when applicable (breast, prostate)
Biomarker values documented and incorporated into prognostic staging
Histologic grade recorded per site-specific grading system
Unknown components recorded as X, not left blank
Multiple primaries staged independently per AJCC rules
Staging date of diagnosis documented
No conflicting staging data between summary and supporting documents
Output formatted for cancer registry abstraction compatibility
Guidelines
Always use the AJCC 8th edition unless the diagnosis date falls before January 1, 2018 (use 7th edition for diagnoses before that date)
Never upstage or downstage based on clinical suspicion alone — staging requires documented evidence
Clinical stage is never changed after it is assigned; pathologic stage is a separate, additional classification
For breast cancer, both anatomic stage and prognostic stage must be recorded
Document the method of M1 confirmation (biopsy-proven vs. imaging-based)
When sentinel lymph node biopsy is performed, use the (sn) suffix on the N category
Flag any staging discrepancies between clinical and pathologic classifications for tumor board review
Include ICD-O-3 histology code to ensure correct chapter selection